Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial-Reference-Cited by-同舟云学术

Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial

Published:2021-01 Issue:1 Volume:9 Page:69-84
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

Lee Laurie A,Bailes Zelie,Barnes Neil,Boulet Louis-Philippe,Edwards Dawn,Fowler Andrew,Hanania Nicola A,Kerstjens Huib A M,Kerwin Edward,Nathan Robert,Oppenheimer John,Papi Alberto,Pascoe Steven,Brusselle Guy,Peachey Guy,Sule Neal,Tabberer Maggie,Pavord Ian D

Funder

GlaxoSmithKline foundation

AstraZeneca

Chiesi Farmaceutici

Menarini Group

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference24 articles.

1. 2020 GINA report, global strategy for asthma management and prevention,2020

2. Fluticasone furoate (FF)/vilanterol (100/25 mcg or 200/25 mcg) or FF (100 mcg) in persistent asthma;Bernstein;J Asthma,2015